Home Life Sciences Neutropenia pipeline Research Report 2017

Neutropenia pipeline Research Report 2017

86
SHARE

Neutropenia Pipeline And Therapeutics Development H1 2017

Neutropenia pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Sample copy is available at https://www.marketinsightsreports.com/reports/0504516/neutropenia-pipeline-and-therapeutics-development-h1-2017/inquiry

Companies Involved in Neutropenia Therapeutics Development are Adello Biologics LLC,Apotex Inc,Arven Ilac,BeyondSpring Pharmaceuticals Inc,Cellerant Therapeutics Inc,Cleveland BioLabs Inc,Coherus BioSciences Inc,Dr. Reddy’s Laboratories Ltd,Eurofarma Laboratorios SA,Intas Pharmaceuticals Ltd,Ligand Pharmaceuticals Inc,Lupin Ltd,Mycenax Biotech Inc,Prolong Pharmaceuticals LLC,Richter Gedeon Nyrt,Sandoz International GmbH,USV Pvt Ltd.

Drug Profiles discussed in this research are ACN-8337 ,ARVMIC-02 ,CBLB-612 ,filgrastim ,filgrastim biosimilar ,LG-7455 ,pegfilgrastim ,pegfilgrastim (recombinant) ,pegfilgrastim biosimilar ,plinabulin ,romyelocel-L ,ST-7 ,tamibarotene.

The Neutropenia pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 2, 1, 4, 3, 1, 8 and 3 respectively.

Get this report at https://www.marketinsightsreports.com/report/purchase/0504516?mode=su

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • he pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

LEAVE A REPLY

Please enter your comment!
Please enter your name here